ArticleBone & joint open2025
Birmingham Hip Resurfacing: a retrospective cohort study of clinical, biochemical, and radiological outcomes in a non-designer centre at minimum 15 years' follow-up.
Article in Bone & joint open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Although the use of metal-on-metal (MoM) implants in total hip arthroplasty (THA) remains a topic of controversy, prior literature has reported satisfactory ten-year clinical and radiological outcomes following Birmingham Hip Resurfacing (BHR), subsequently resulting in a recent Orthopaedic Data Evaluation Panel (ODEP) rating of 15 A*. Therefore, the purpose of this study was to evaluate the functional outcomes, radiological outcomes, and revision rates following BHR at a minimum of 15 years' follow-up in a non-designer centre. Methods: Two investigators performed a retrospective review to identify consecutive patients who underwent BHR in our institution over a seven-year period (2003 to 2009, at minimum 15 years' follow-up) in a non-designer centre. Evaluation of clinical (Oxford Hip Scores (OHS)), biochemical (cobalt and chromium levels), and radiological (plain film radiographs) outcomes was carried out. Survivorship analysis was performed using Kaplan-Meier curves, with all-cause surgical revision defined as a definitive endpoint for analysis. Descriptive statistical analysis was carried out. Results: Overall, 96 patients (86 males) at a mean age of 51.4 years (SD 9.9; 27 to 69) underwent 105 BHR procedures (nine bilateral) with at least 15 years' minimum follow-up. Mean OHS was 38.3 (SD 9.6; 17 to 48) at 15-year minimum follow-up. The overall survivorship was 94.3% at 15 years post BHR, with an all-cause revision rate of 5.7%. Only eight BHR prostheses (8.2%) had radiolucent lines on plain films, none of which were listed for revision at the time of latest follow-up, while 32 patients had undergone MRI at 170 months (SD 54.9; 6 to 249) post BHR, with evidence of fluid collection, aseptic lymphocyte-dominant vasculitis-associated lesion, and metallosis identified on the MRI of four patients, four patients, and one patient, respectively. For 98.4% (60/61) of patients, cobalt and chromium values were either within normal limits (68.9%, n = 42) or less than double the upper limit of normal (29.5%, n = 18). Conclusion: This study found that BHR demonstrates an acceptable survivorship of 94% at 15 years of minimum follow-up, with satisfactory clinical and radiological outcomes to reflect this low all-cause revision rate in a non-designer centre.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.